Assessment of anti-arrhythmic activity of antipsychotic drugs in an animal model: Influence of non-cardiac α1-adrenergic receptors

European Journal of Pharmacology

Volumn 748, Issue , 2015, Pages 10-17

  Mow, Tomas ^a   Frederiksen, Kristen ^a   Thomsen, Morten B ^b  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Action potentials; Adrenergic receptors; Animal model; Cardiac arrhythmia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CLOFILIUM; DELAYED RECTIFIER POTASSIUM CHANNEL; DOFETILIDE; HALOPERIDOL; METHOXAMINE; OLANZAPINE; RISPERIDONE; SERTINDOLE; ANTIARRHYTHMIC AGENT; NEUROLEPTIC AGENT; POTASSIUM;

ACTION POTENTIAL DURATION; ADRENERGIC RECEPTOR BLOCKING; ALPHA ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CHINESE HAMSTER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG RECEPTOR BINDING; EX VIVO STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PURKINJE FIBER; RABBIT MODEL; RAT; TORSADE DES POINTES; ACTION POTENTIAL; ANIMAL; ANIMAL MODEL; BLOOD PRESSURE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HAMSTER; METABOLISM; PHYSIOLOGY; RABBIT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; FEMALE; MALE; MODELS, ANIMAL; POTASSIUM; PURKINJE FIBERS; RABBITS; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84920265044     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.12.012     Document Type: Article

References (60)

1. C. Antzelevitch, A. Burashnikov, S. Sicouri, and L. Belardinelli Electrophysiologic basis for the antiarrhythmic actions of ranolazine Heart Rhythm. 8 2011 1281 1290
2. M. Apkon, and J.M. Nerbonne Alpha 1-adrenergic agonists selectively suppress voltage-dependent K+ current in rat ventricular myocytes Proc. Natl. Acad. Sci. U.S.A. 85 1988 8756 8760
3. J. Arnt, and T. Skarsfeldt Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology Off. Publ. Am. Coll. Neuropsychopharmacol 18 1998 63 101
4. T.R. Barnes, and M.A. McPhillips Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics Br. J. Psychiatry Suppl. 1999 34 43
5. A.J. Batey, and S.J. Coker Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes Br. J. Pharmacol. 135 2002 1003 1012
6. S. Brown Excess mortality of schizophrenia. A meta-analysis Br. J. Psychiatry J. Ment. Sci 171 1997 502 508
7. N.A. Buckley, and P. Sanders Cardiovascular adverse effects of antipsychotic drugs Drug Saf. Int. J. Med. Toxicol. Drug Exp 23 2000 215 228
8. A. Burashnikov, and C. Antzelevitch Differences in the electrophysiologic response of four canine ventricular cell types to alpha 1-adrenergic agonists Cardiovasc. Res. 43 1999 901 908
9. L. Carlsson The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol. Ther. 119 2008 160 167
10. L. Carlsson, C. Abrahamsson, B. Andersson, G. Duker, and G. Schiller-Linhardt Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations Cardiovasc. Res. 27 1993 2186 2193
11. L. Carlsson, O. Almgren, and G. Duker QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions J. Cardiovasc. Pharmacol. 16 1990 276 285
12. L. Carlsson, L. Drews, and G. Duker Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload J. Pharmacol. Exp. Ther. 279 1996 231 239
13. W.J. Crumb, S. Ekins, R.D. Sarazan, J.H. Wikel, S.A. Wrighton, C. Carlson, and C.M. Beasley Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis Pharm. Res. 23 2006 1133 1143
14. K. Derakhchan, R. Cardinal, S. Brunet, D. Klug, C. Pharand, T. Kus̈, and B.I. Sasyniuk Polymorphic ventricular tachycardias induced by d-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry Cardiovasc. Res. 38 1998 617 630
15. E. Detre, M.B. Thomsen, J.D. Beekman, K.-U. Petersen, and M.A. Vos Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes Br. J. Pharmacol. 145 2005 397 404
16. F. Dessertenne Ventricular tachycardia with 2 variable opposing foci Arch. Mal. Coeur. Vaiss. 59 1966 263 272
17. G.C. Digby, A.R. Pérez Riera, R. Barbosa Barros, C.S. Simpson, D.P. Redfearn, M. Methot, F. Femenía, and A. Baranchuk Acquired long QT interval: a case series of multifactorial QT prolongation Clin. Cardiol. 34 2011 577 582
18. L. Eckardt, G. Breithardt, and W. Haverkamp Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation J. Pharmacol. Exp. Ther. 300 2002 64 71
19. M. Endoh, T. Hiramoto, A. Ishihata, M. Takanashi, and J. Inui Myocardial alpha 1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylinositol metabolism. Species differences in receptor distribution and the intracellular coupling process in mammalian ventricular myocardium Circ. Res. 68 1991 1179 1190
20. A. Farkas, A.J. Batey, and S.J. Coker How to measure electrocardiographic QT interval in the anaesthetized rabbit J. Pharmacol. Toxicol. Methods 50 2004 175 185
21. A. Farkas, J. Dempster, and S.J. Coker Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model Br. J. Pharmacol. 154 2008 958 970
22. A.S. Farkas, K. Acsai, A. Tóth, L. Dézsi, S. Orosz, T. Forster, M. Csanády, J.G. Papp, A. Varró, and A. Farkas Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts Eur. J. Pharmacol. 537 2006 118 125
23. D. Fedida, A.P. Braun, and W.R. Giles Alpha 1-adrenoceptors reduce background K+ current in rabbit ventricular myocytes J. Physiol. 441 1991 673 684
24. R.R. Fenichel, M. Malik, C. Antzelevitch, M. Sanguinetti, D.M. Roden, S.G. Priori, J.N. Ruskin, R.J. Lipicky, L.R. Cantilena Independent Academic Task Force Drug-induced torsades de pointes and implications for drug development J. Cardiovasc. Electrophysiol. 15 2004 475 495
25. P. Greengrass, and R. Bremner Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors Eur. J. Pharmacol. 55 1979 323 326
26. S. Hamer, and P.M. Haddad Adverse effects of antipsychotics as outcome measures Br. J. Psychiatry Suppl. 50 2007 s64 s70
27. E.P. Harrigan, J.J. Miceli, R. Anziano, E. Watsky, K.R. Reeves, N.R. Cutler, J. Sramek, T. Shiovitz, and M. Middle A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition J. Clin. Psychopharmacol. 24 2004 62 69
28. W. Haverkamp, G. Breithardt, A.J. Camm, M.J. Janse, M.R. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, and R. Shah The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the european society of cardiology Cardiovasc. Res. 47 2000 219 233
29. W. Haverkamp, L. Eckardt, J. Matz, and K. Frederiksen Sertindole: cardiac electrophysiological profile Int. J. Psychiatry Clin. Pract. 6 2002 11 20
30. X. Ji, W. Zhao, D. Cao, Q. Shi, and X. Wang Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1 Acta Pharmacol. Sin. 32 2011 182 187
31. J. Kramer, C.A. Obejero-Paz, G. Myatt, Y.A. Kuryshev, A. Bruening-Wright, J.S. Verducci, and A.M. Brown MICE models: superior to the HERG model in predicting Torsade de Pointes Sci. Rep 3 2013 2100
32. K.P. Letsas, M. Efremidis, S.P. Kounas, L.K. Pappas, G. Gavrielatos, I.P. Alexanian, N.P. Dimopoulos, G.S. Filippatos, A. Sideris, and F. Kardaras Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors Clin. Res. Cardiol. Off. J. Ger. Card. Soc 98 2009 208 212
33. J.Y.T. Leung, C.C.Y. Pang, R.M. Procyshyn, and A.M. Barr Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats Vascul. Pharmacol 62 2014 143 149
34. A. Lundby, M.N. Andersen, A.B. Steffensen, H. Horn, C.D. Kelstrup, C. Francavilla, L.J. Jensen, N. Schmitt, M.B. Thomsen, and J.V. Olsen In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling Sci. Signal. 6 2013 rs11
35. R. Maroto, A. Raso, T.G. Wood, A. Kurosky, B. Martinac, and O.P. Hamill TRPC1 forms the stretch-activated cation channel in vertebrate cells Nat. Cell Biol. 7 2005 179 185
36. L. Nalos, R. Varkevisser, M.K.B. Jonsson, M.J.C. Houtman, J.D. Beekman, R. van der Nagel, M.B. Thomsen, G. Duker, P. Sartipy, T.P. de Boer, M. Peschar, M.B. Rook, T.a.B. van Veen, M.a.G. van der Heyden, and M.A. Vos Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes Br. J. Pharmacol. 165 2012 467 478
37. J. Nielsen, C. Graff, J.K. Kanters, E. Toft, D. Taylor, and J.M. Meyer Assessing QT interval prolongation and its associated risks with antipsychotics CNS Drugs 25 2011 473 490
38. Z. Nourian, T. Mow, D. Muftic, S. Burek, M.L. Pedersen, J. Matz, and M.J. Mulvany Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function Psychopharmacology (Berl.) 199 2008 15 27
39. Z. Nourian, T. Mow, D. Muftic, S. Burek, M.L. Pedersen, J. Matz, and M.J. Mulvany Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function Psychopharmacology (Berl.) 199 2008 15 27
40. Z. Nourian, M.J. Mulvany, K.B. Nielsen, D.S. Pickering, and T. Kristensen The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors Eur. J. Pharmacol. 596 2008 32 40
41. A. Oros, J.D.M. Beekman, and M.A. Vos The canine model with chronic, complete atrio-ventricular block Pharmacol. Ther. 119 2008 168 178
42. E. Raschi, E. Poluzzi, B. Godman, A. Koci, U. Moretti, M. Kalaba, M. Bennie, C. Barbui, B. Wettermark, M. Sturkenboom, and F. De Ponti Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe PLoS One 8 2013 e81208
43. M.J. Reiter, K.D. Stromberg, T.A. Whitman, P.B. Adamson, D.G. Benditt, and M.R. Gold Influence of intracardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf trial Circ. Arrhythm. Electrophysiol 6 2013 272 278
44. E. Richelson Receptor pharmacology of neuroleptics: relation to clinical effects J. Clin. Psychiatry 60 Suppl. 10 1999 5 14
45. R.B. Robinson, Q.Y. Liu, and M.R. Rosen Ionic basis for action potential prolongation by phenylephrine in canine epicardial myocytes J. Cardiovasc. Electrophysiol. 11 2000 70 76
46. J.S. Silvestre, M.F. O'Neill, and J.R. Prous Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics J. Psychopharmacol. Oxf. Engl 28 2014 329 340
47. J.J. Sramek, R.J. Mack, W. Awni, J. Hourani, S.S. Jhee, S. Barto, and N.R. Cutler Two rapid-dose titrations of sertindole in patients with schizophrenia J. Clin. Psychopharmacol. 17 1997 419 422
48. C. Stanniland, and D. Taylor Tolerability of atypical antipsychotics Drug Saf. Int. J. Med. Toxicol. Drug Exp 22 2000 195 214
49. M. Takahira, M. Sakurai, N. Sakurada, and K. Sugiyama Fenamates and diltiazem modulate lipid-sensitive mechano-gated 2P domain K(+) channels Pflüg. Arch. Eur. J. Physiol 451 2005 474 478
50. M.B. Thomsen, J. Matz, P.G.A. Volders, and M.A. Vos Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias Pharmacol. Ther. 112 2006 150 170
51. M.B. Thomsen, E.A. Sosunov, E.P. Anyukhovsky, N. Ozgen, P.A. Boyden, and M.R. Rosen Deleting the accessory subunit KChIP2 results in loss of I(to,f) and increased I(K,slow) that maintains normal action potential configuration Heart Rhythm. 6 2009 370 377
52. M.B. Thomsen, S.C. Verduyn, M. Stengl, J.D.M. Beekman, G. de Pater, J. van Opstal, P.G.A. Volders, and M.A. Vos Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs Circulation 110 2004 2453 2459
53. M.B. Thomsen, P.G.A. Volders, J.D.M. Beekman, J. Matz, and M.A. Vos Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes J. Am. Coll. Cardiol. 48 2006 1268 1276
54. M.B. Thomsen, P.G.A. Volders, M. Stengl, R.L.H.M.G. Spätjens, J.D.M. Beekman, U. Bischoff, M.A. Kall, K. Frederiksen, J. Matz, and M.A. Vos Electrophysiological safety of sertindole in dogs with normal and remodeled hearts J. Pharmacol. Exp. Ther. 307 2003 776 784
55. N.A. Trayanova, J. Constantino, and V. Gurev Models of stretch-activated ventricular arrhythmias J. Electrocardiol. 43 2010 479 485
56. S.-J. Tsai Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1 Med. Hypotheses 70 2008 548 550
57. D. Vincze, A.S. Farkas, L. Rudas, P. Makra, N. Csík, I. Leprán, T. Forster, M. Csanády, J.G. Papp, A. Varró, and A. Farkas Relevance of anaesthesia for dofetilide-induced torsades de pointes in alpha1-adrenoceptor-stimulated rabbits Br. J. Pharmacol. 153 2008 75 89
58. P.G. Volders, A. Kulcs̈ar, M.A. Vos, K.R. Sipido, H.J. Wellens, R. Lazzara, and B. Szabo Similarities between early and delayed afterdepolarizations induced by isoproterenol in canine ventricular myocytes Cardiovasc. Res. 34 1997 348 359
59. M.A. Vos, J.M. van Opstal, J.D. Leunissen, and S.C. Verduyn Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias Pharmacol. Ther. 92 2001 109 122
60. W.-Q. Wang, C. Robertson, A.K. Dhalla, and L. Belardinelli Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits J. Pharmacol. Exp. Ther. 325 2008 875 881